AVROBIO gains on 'rare pediatric disease' tag for experimental gene therapy

Tectonic Therapeutic

20/09/2022 13:23

** Shares of gene therapy developer AVROBIO Inc  AVRO.O 
gain ~6% to 85 cents premarket
    ** Co receives "rare pediatric disease" tag from U.S. FDA
for its experimental gene therapy, AVR-RD-04, for treating
cystinosis  urn:newsml:reuters.com:*:nBw4g0rJfa
    ** Cystinosis is a genetic condition that can impact all the
organs and tissues, but mainly affects the kidneys and eyes
    ** AVR-RD-04 is currently being evaluated in an early-to
mid-stage study
    ** Companies that receive approval for a rare pediatric
disease drug may be eligible to receive a transferable voucher
for a priority review of an application for another drug
    ** As of last close, stock down ~79% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))